The latest China pharma news, including the upcoming first domestic approval for a foreign COVID-19 vaccine in June; the potential of Western China as a manufacturing hub; and EpimAb’s plan…
Singapore – despite its modest USD 1.22 billion domestic market – has long been one of Asia’s leading biopharmaceutical hubs and a magnet for top talent. Multitudes of biopharma and…
In March 2018, German pharma player Boehringer Ingelheim (BI)‘s Consanas Rehabilitation and the Shanghai International Medical Center (SIMC) jointly established a Rehabilitation Medicine Center for stroke patients with the mission…
Kevin Rufang Huang, president and founder of the Chinese Organization for Rare Disorders (CORD), outlines the findings of the first ever analysis into rare disease public insurance coverage across key…
The latest from Chinese pharma, including a new deal between AstraZeneca and Junshi Biosciences; Innoforce and dMed’s R&D collab; and investment news on Clover Biopharmaceuticals, Sciwind Biosciences, and Gensciences. …
As the most important pharma hub in its region, and one of the most important globally, many companies look to launch new products in Singapore first before expanding to other…
One of the largest domestic pharma companies in China (ranking number one from 2014 to 2019), Yangtze River Pharmaceutical Group (YRPG) is so-named for its location in Taizhou, Jiangsu Province,…
At USD 150 billion, Asia-Pacific is home to the world’s second largest medtech market and, with a CAGR of nine percent, certainly its most dynamic. Chronic underfunding of healthcare systems…
HiFiBiO Therapeutics cofounder, CEO and CSO Dr Liang Schweizer fits the profile of a Chinese biotech CEO to a T: advanced degrees in different scientific fields, including a master’s in…
Writing in the February edition of DIA’s Global Forum magazine, Xu Wang of Novo Nordisk Pharma China and Xiaoxi Wang from the Shanghai Center for Drug Evaluation & Inspection analyse…
Eric Bouteiller examines the most recent update to China’s National Reimbursement Drug List, the positive impact that a de facto annual review has had on drug approval timelines, and why…
The latest news from Indian pharma, including a 200 percent boost for the country’s pharmaceutical industry in the latest national budget; predictions of rapid growth in the coming decade; Cipla’s…
See our Cookie Privacy Policy Here